BR112017019620A2 - ?roedor geneticamente modificado, célula ou tecido, métodos para produção de um roedor geneticamente modificado e de uma população de neurônios motores, métodos para seleção de um agente candidato para modular a disfunção neuronal motora e de um agente candidato para redução do estresse oxidativo em um neurônio motor, ácido nucleico, e, célula de roedor? - Google Patents
?roedor geneticamente modificado, célula ou tecido, métodos para produção de um roedor geneticamente modificado e de uma população de neurônios motores, métodos para seleção de um agente candidato para modular a disfunção neuronal motora e de um agente candidato para redução do estresse oxidativo em um neurônio motor, ácido nucleico, e, célula de roedor?Info
- Publication number
- BR112017019620A2 BR112017019620A2 BR112017019620-4A BR112017019620A BR112017019620A2 BR 112017019620 A2 BR112017019620 A2 BR 112017019620A2 BR 112017019620 A BR112017019620 A BR 112017019620A BR 112017019620 A2 BR112017019620 A2 BR 112017019620A2
- Authority
- BR
- Brazil
- Prior art keywords
- genetically modified
- methods
- cell
- rodent
- candidate agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000006764 neuronal dysfunction Effects 0.000 title abstract 3
- 241000283984 Rodentia Species 0.000 title 3
- 210000004027 cell Anatomy 0.000 title 2
- 239000003795 chemical substances by application Substances 0.000 title 2
- 210000002161 motor neuron Anatomy 0.000 title 2
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 230000036542 oxidative stress Effects 0.000 title 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 108700028369 Alleles Proteins 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562133909P | 2015-03-16 | 2015-03-16 | |
| US62/133909 | 2015-03-16 | ||
| US201562250229P | 2015-11-03 | 2015-11-03 | |
| US62/250229 | 2015-11-03 | ||
| PCT/US2016/022685 WO2016149398A1 (en) | 2015-03-16 | 2016-03-16 | Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017019620A2 true BR112017019620A2 (pt) | 2018-05-15 |
Family
ID=55646893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017019620-4A BR112017019620A2 (pt) | 2015-03-16 | 2016-03-16 | ?roedor geneticamente modificado, célula ou tecido, métodos para produção de um roedor geneticamente modificado e de uma população de neurônios motores, métodos para seleção de um agente candidato para modular a disfunção neuronal motora e de um agente candidato para redução do estresse oxidativo em um neurônio motor, ácido nucleico, e, célula de roedor? |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10285387B2 (enExample) |
| EP (2) | EP3270688B1 (enExample) |
| JP (4) | JP6600694B2 (enExample) |
| KR (2) | KR102616160B1 (enExample) |
| CN (1) | CN107690279B (enExample) |
| AU (2) | AU2016233250C1 (enExample) |
| BR (1) | BR112017019620A2 (enExample) |
| CA (1) | CA2978096C (enExample) |
| ES (2) | ES2830173T3 (enExample) |
| IL (2) | IL274285B (enExample) |
| MX (2) | MX380521B (enExample) |
| RU (1) | RU2744831C2 (enExample) |
| SG (2) | SG10201912899QA (enExample) |
| WO (1) | WO2016149398A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL294443A (en) * | 2013-08-07 | 2022-09-01 | Regeneron Pharma | Lincrna-deficient non-human animals |
| US10781453B2 (en) * | 2016-09-30 | 2020-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus |
| CN111793607B (zh) * | 2017-07-28 | 2022-05-17 | 杨涛 | 定向诱导hiPSC分化为神经细胞体系中培养神经元细胞的基础培养基 |
| CN107586791B (zh) * | 2017-10-26 | 2018-09-21 | 四川省人民医院 | 一种共济失调动物模型的构建方法以及应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566089B1 (en) | 1996-09-04 | 2003-05-20 | Tularik Inc. | Cell-based drug screens for regulators of gene expression |
| US6358508B1 (en) | 1997-06-11 | 2002-03-19 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR9 |
| US6949358B1 (en) | 1997-06-11 | 2005-09-27 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor TR9 |
| WO1999005266A2 (en) | 1997-07-26 | 1999-02-04 | Wisconsin Alumni Research Foundation | Trans-species nuclear transfer |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AUPR451401A0 (en) | 2001-04-20 | 2001-05-24 | Monash University | A method of nuclear transfer |
| US20050069540A1 (en) | 2001-12-17 | 2005-03-31 | Jinqi Liu | Treating b-cell mediated diseases by modulating dr6 activity |
| US7612250B2 (en) | 2002-07-29 | 2009-11-03 | Trustees Of Tufts College | Nuclear transfer embryo formation method |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| CN101117633B (zh) | 2006-08-03 | 2011-07-20 | 上海交通大学附属儿童医院 | 一种细胞核移植方法 |
| CN101616934A (zh) * | 2006-12-22 | 2009-12-30 | 健泰科生物技术公司 | 抑制dr6结合app的dr6抗体及其在治疗神经学病症中的用途 |
| WO2008080045A2 (en) | 2006-12-22 | 2008-07-03 | Genentech, Inc. | Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders |
| TWI476280B (zh) | 2008-03-07 | 2015-03-11 | Regeneron Pharma | 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠 |
| WO2009152463A2 (en) | 2008-06-12 | 2009-12-17 | Genentech, Inc. | Method for screening for compounds that inhibit neurodegeneration |
| KR20110089185A (ko) | 2008-11-25 | 2011-08-04 | 바이오겐 아이덱 엠에이 인코포레이티드 | 신경계 세포의 생존을 촉진하기 위한 ｄｒ６ 및 ｐ７５ 길항제의 용도 |
| TW201034684A (en) * | 2009-02-18 | 2010-10-01 | Genentech Inc | Method for inhibiting neurodegeneration |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| US8518392B2 (en) | 2009-08-14 | 2013-08-27 | Regeneron Pharmaceuticals, Inc. | Promoter-regulated differentiation-dependent self-deleting cassette |
| TR201903376T4 (tr) | 2009-10-29 | 2019-04-22 | Regeneron Pharma | Çok fonksiyonlu alleller. |
| JP6275120B2 (ja) | 2012-04-25 | 2018-02-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 大きい標的化ベクターによるヌクレアーゼ媒介標的化 |
| JP6475172B2 (ja) | 2013-02-20 | 2019-02-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ラットの遺伝子組換え |
| EP3456831B1 (en) | 2013-04-16 | 2021-07-14 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
| MX388127B (es) | 2013-12-11 | 2025-03-19 | Regeneron Pharma | Metodos y composiciones para la modificacion dirigida de un genoma. |
-
2016
- 2016-03-16 BR BR112017019620-4A patent/BR112017019620A2/pt not_active Application Discontinuation
- 2016-03-16 ES ES16713691T patent/ES2830173T3/es active Active
- 2016-03-16 CA CA2978096A patent/CA2978096C/en active Active
- 2016-03-16 WO PCT/US2016/022685 patent/WO2016149398A1/en not_active Ceased
- 2016-03-16 MX MX2017011918A patent/MX380521B/es unknown
- 2016-03-16 AU AU2016233250A patent/AU2016233250C1/en active Active
- 2016-03-16 CN CN201680016100.0A patent/CN107690279B/zh active Active
- 2016-03-16 SG SG10201912899QA patent/SG10201912899QA/en unknown
- 2016-03-16 JP JP2017548965A patent/JP6600694B2/ja active Active
- 2016-03-16 RU RU2017135557A patent/RU2744831C2/ru active
- 2016-03-16 US US15/072,286 patent/US10285387B2/en active Active
- 2016-03-16 EP EP16713691.0A patent/EP3270688B1/en active Active
- 2016-03-16 IL IL274285A patent/IL274285B/en unknown
- 2016-03-16 KR KR1020227024994A patent/KR102616160B1/ko active Active
- 2016-03-16 ES ES20159001T patent/ES2955841T3/es active Active
- 2016-03-16 KR KR1020177025830A patent/KR102424119B1/ko active Active
- 2016-03-16 SG SG11201706809WA patent/SG11201706809WA/en unknown
- 2016-03-16 EP EP20159001.5A patent/EP3685662B9/en active Active
-
2017
- 2017-09-05 IL IL254333A patent/IL254333B/en active IP Right Grant
- 2017-09-15 MX MX2021002852A patent/MX2021002852A/es unknown
-
2019
- 2019-03-07 US US16/295,543 patent/US20190261610A1/en not_active Abandoned
- 2019-10-07 JP JP2019184476A patent/JP2020005660A/ja active Pending
-
2020
- 2020-09-11 JP JP2020152914A patent/JP7193509B2/ja active Active
-
2021
- 2021-07-07 US US17/368,933 patent/US20210392865A1/en not_active Abandoned
- 2021-12-29 JP JP2021215389A patent/JP2022048157A/ja not_active Withdrawn
-
2022
- 2022-02-07 AU AU2022200784A patent/AU2022200784B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021009163A2 (es) | Composiciones de agente de arni de proteína precursora de amiloide (app) y método de uso de las mismas | |
| BR112019022538A8 (pt) | Técnicas para pareamento comportamental em um sistema de centro de contato | |
| BR112017010498A2 (pt) | anticorpos tau humanizados em doença de alzheimer | |
| CO2018006590A2 (es) | Métodos y composiciones para el tratamiento de un trastorno asociado a serpinc1 | |
| MX381216B (es) | Animales no humanos que tienen una expansion de repeticiones de hexanucleotidos en un locus c9orf72. | |
| CR20170190A (es) | Composiciones y métodos para inhibir la expresión del gen ha01 (hidroxiácido-oxidasa 1(glicolato-oxidasa)) | |
| BR112017018728A2 (pt) | sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada | |
| BR112017019620A2 (pt) | ?roedor geneticamente modificado, célula ou tecido, métodos para produção de um roedor geneticamente modificado e de uma população de neurônios motores, métodos para seleção de um agente candidato para modular a disfunção neuronal motora e de um agente candidato para redução do estresse oxidativo em um neurônio motor, ácido nucleico, e, célula de roedor? | |
| CO2021002691A2 (es) | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1) | |
| MX2020011415A (es) | Metodos de usar zscan4 para rejuvenecer celulas humanas. | |
| MX2015009963A (es) | Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía. | |
| UY34701A (es) | Formas sólidas de un profármaco de nucleótidos de tiofosforamidato | |
| UY31816A (es) | Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras | |
| SG195191A1 (en) | Methods and compositions of predicting activity of retinoid x receptor modulator | |
| BR112016008409A2 (pt) | Uso de um agente inibidor de masp-2 que inibe a ativação de complemento dependente de masp-2 | |
| Kolosova et al. | Senescence-accelerated OXYS rats: A genetic model of premature aging and age-related diseases | |
| BR112018067597A8 (pt) | célula progenitora de fígado adulto, população celular, material biológico, composição, método para avaliar a eficácia, o metabolismo, a estabilidade e/ou a toxicidade de um ou mais compostos, uso da célula ou população celular e kit | |
| BR112013023960A2 (pt) | método de análise de uma amostra de sangue de um indivíduo para a presença de um marcador de doença | |
| PH12019500422A1 (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| BR112016026245A2 (pt) | ?roedor, e, métodos para fazer um roedor humanizado, para fazer um camundongo com dpp4 humanizado, para fazer um roedor transgênico humanizado e para determinar a eficácia terapêutica in vivo de um antagonista da dpp4 específica para humanos no roedor? | |
| Familtseva et al. | Mitochondrial mitophagy in mesenteric artery remodeling in hyperhomocysteinemia | |
| BR112017007066A2 (pt) | composições e métodos para melhorar a mobilidade ou a atividade, ou tratar a debilidade | |
| BR112016010342A2 (pt) | sequência de rna isolada ou sintética, sequência de dna, vetor que permite a expressão de uma sequência de rna, célula que compreende uma sequência de rna, composição que compreende uma sequência de rna, utilização de uma sequência de rna, camundongo transgênico, método que permite avaliar a eficácia cosmética de um composto de teste, e, método que permite avaliar a eficácia terapêutica de um composto de teste | |
| Sidor et al. | The impact of early life immune challenge on behavior and microglia during postnatal development | |
| Tseng et al. | The single nucleotide variant at c. 662A> G in human RRM2B is a loss‐of‐function mutation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |